Slingshot members are tracking this event:

Novartis (NVS) to submit biosimilar Pegfilgrastim for bone marrow stimulation to FDA in early 2019

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Biosimilar, Pegfilgrastim, Fda Review, Bone Marrow Stimulation